Luke, I Am Your Daddy
All book sale proceeds and donations will help fund Restrictive Cardiomyopathy research.
100% of your donation will help fund Restrictive Cardiomyopathy research.
We are in contact with organizations working towards a cure and plan to help further their research with the funds raised.
We are in contact with Florida Atlantic University College of Medicine where Dr. Xupei Huang and his team are working diligently to find a cure for Restrictive Cardiomyopathy.
Among the key findings of their research, Dr. Huang and his team have found that in Restrictive Cardiomyopathy, calcium does not bind or properly drop off in the cardiac muscles and the muscle fibers have a hypersensitivity to the calcium. Therefore, traditional drug therapies such as calcium blockers do not work in restrictive cardiomyopathy. Huang is hoping to develop drugs that will reduce the calcium sensitivity and accelerate the calcium drop off from the protein in these diseased hearts.
MyoKardia is dedicated to revolutionizing the treatment of genetic heart diseases. The company's initial focus includes hypertrophic and dilated cardiomyopathy (HCM and DCM), diseases for which there have been no treatment advances in more than 50 years.
By combining leading-edge cardiovascular genetics with recent advances in heart muscle biochemistry, MyoKardia seeks to usher in an era of precision medicine that will dramatically improve the treatment of cardiomyopathies and make a meaningful difference in the lives of millions of people suffering from cardiovascular diseases. Available treatments for patients suffering from these forms of heart disease have been approved for other illnesses and only treat the symptoms of their disease. MyoKardia’s approach targets the genetic mutations that are the underlying causes of cardiomyopathy, addressing the fundamental mechanisms of the disease. This genetically targeted approach has the potential to revolutionize the treatment of cardiomyopathies, and ultimately a broader spectrum of cardiovascular disease, including heart failure.
The Sarcomeric Human Cardiomyopathy Registry (ShaRe) has been set up to advance our understanding of Hypertrophic Cardiomyopathy (HCM) and Dilated Cardiomyopathy (DCM). These heritable heart diseases are caused by mutations in the protein genes of the sarcomere, the fundamental contractile unit of heart muscle. They are genetically passed on in families in an autosomal dominant pattern of inheritance. The prevalence of these diseases, taken together, is usually estimated at 1 in 500 individuals in the general population.
Viteava has a drug entering clinical trials that has the potential to alleviate the effects of Restrictive Cardiomyopathy. The drug is a derivative of Epigallocatechin-3-gallate (EGCG) with improved bioavailability.
A major challenge in extrapolating the biological activities of EGCG to improved clinical benefits, is its bioavailability. Viteava’s innovative candidate drugs are modifications of the EGCG chemical structure resulting in improved bioavailability. VPE001 is a prodrug of EGCG with improved potency and bioavailability.
(http://viteava.com/pipeline/)